Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2014

Open Access 01-02-2014 | Research article

Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset

Authors: Paul R Dominguez-Gutierrez, Angela Ceribelli, Minoru Satoh, Eric S Sobel, Westley H Reeves, Edward KL Chan

Published in: Arthritis Research & Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

Our recent data showed that signal transducers and activators of transcription 1 (STAT1), adenosine deaminase acting on RNA (ADAR), C-C motif chemokine ligand 2 (CCL2), and C-X-C motif chemokine 10 (CXCL10) were significantly elevated in a systemic lupus erythematosus (SLE) cohort compared to healthy donors. High and low STAT1 subsets were identified in SLE patient visits. The present study analyzed the correlation of common treatments used in SLE with the levels of these biomarkers.

Methods

Peripheral blood leukocytes were collected from 65 healthy donors and 103 SLE patients, of whom 60 had samples from two or more visits. Total RNA was isolated and analyzed for the expression of mRNA and microRNA using Taqman real-time polymerase chain reaction (PCR) assays. Relative expression of interferon signature genes, CCL2, and CXCL10 were determined by the ΔΔCT method. Results were correlated with therapy using prednisone, mycophenolate mofetil, and hydroxychloroquine and analyzed by Wilcoxon/Kruskal-Wallis test and Fisher’s exact test.

Results

CCL2 and CXCL10 were significantly higher in untreated patients compared to treated patients, however, in high STAT1 patient visits there is no significant difference between treated and untreated patients’ visits. When comparing linear regression fits of interferon (IFN) score with CCL2 and CXCL10, untreated patients and high STAT1 patients displayed significantly higher slopes compared to treated patients. There was no significant difference between the slopes of high STAT1 and untreated patients indicating that CCL2 and CXCL10 were correlated with type-I IFN in high STAT1 patients similar to that in untreated patients. CCL2 and CXCL10 levels in the high STAT1 subset remained high in treated patient visits compared to those of the low STAT1 subset.

Conclusions

Among the biomarkers analyzed, only CCL2 and CXCL10 showed significantly reduced levels in treated compared to untreated SLE patients. STAT1, CCL2, and CXCL10 are potentially useful indicators of therapeutic action in SLE patients. Further work is needed to determine whether high STAT1 levels convey resistance to therapies commonly used to treat SLE and whether STAT1 inhibitors may have therapeutic implication for these patients.
Appendix
Available only for authorised users
Literature
1.
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003, 100: 2610-2615. 10.1073/pnas.0337679100.CrossRefPubMedPubMedCentral
2.
Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003, 197: 711-723. 10.1084/jem.20021553.CrossRefPubMedPubMedCentral
3.
Crow MK: Interferon pathway activation in systemic lupus erythematosus. Curr Rheumatol Rep. 2005, 7: 463-468. 10.1007/s11926-005-0053-4.CrossRefPubMed
4.
Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J: Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 1982, 216: 429-431. 10.1126/science.6176024.CrossRefPubMed
5.
Karonitsch T, Feierl E, Steiner CW, Dalwigk K, Korb A, Binder N, Rapp A, Steiner G, Scheinecker C, Smolen J, Aringer M: Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum. 2009, 60: 1463-1471. 10.1002/art.24449.CrossRefPubMed
6.
Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, Espe KJ, Li W, Patel DD, Gregersen PK, Behrens TW: Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006, 3: e491-. 10.1371/journal.pmed.0030491.CrossRefPubMedPubMedCentral
7.
Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, Panoskaltsis-Mortari A, Gregersen PK, Behrens TW, Baechler EC: Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009, 60: 3098-3107. 10.1002/art.24803.CrossRefPubMedPubMedCentral
8.
Xia M, Sui Z: Recent developments in CCR2 antagonists. Expert Opin Ther Pat. 2009, 19: 295-303. 10.1517/13543770902755129.CrossRefPubMed
9.
Loetscher M, Loetscher P, Brass N, Meese E, Moser B: Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol. 1998, 28: 3696-3705. 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W.CrossRefPubMed
10.
Weng Y, Siciliano SJ, Waldburger KE, Sirotina-Meisher A, Staruch MJ, Daugherty BL, Gould SL, Springer MS, DeMartino JA: Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998, 273: 18288-18291. 10.1074/jbc.273.29.18288.CrossRefPubMed
11.
Han C, Fu J, Liu Z, Huang H, Luo L, Yin Z: Dipyrithione inhibits IFN-gamma-induced JAK/STAT1 signaling pathway activation and IP-10/CXCL10 expression in RAW264.7 cells. Inflamm Res. 2010, 59: 809-816. 10.1007/s00011-010-0192-6.CrossRefPubMed
12.
13.
Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EKL: MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther. 2011, 13: 229. 10.1186/ar3377.CrossRefPubMedPubMedCentral
14.
Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y, Huang X, Zhou H, de Vries N, Tak PP, Chen S, Shen N: MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009, 60: 1065-1075. 10.1002/art.24436.CrossRefPubMed
15.
Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 2006, 103: 12481-12486. 10.1073/pnas.0605298103.CrossRefPubMedPubMedCentral
16.
Nahid MA, Rivera M, Lucas A, Chan EK, Kesavalu L: Polymicrobial infection with periodontal pathogens specifically enhances microRNA miR-146a in ApoE−/− mice during experimental periodontal disease. Infect Immun. 2011, 79: 1597-1605. 10.1128/IAI.01062-10.CrossRefPubMedPubMedCentral
17.
Nahid MA, Pauley KM, Satoh M, Chan EKL: miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity. J Biol Chem. 2009, 284: 34590-34599. 10.1074/jbc.M109.056317.CrossRefPubMedPubMedCentral
18.
Chan EKL, Ceribelli A, Satoh M: MicroRNA-146a in autoimmunity and innate immune responses. Ann Rheum Dis. 2013, 72: ii90-ii95.CrossRefPubMed
19.
Pauley KM, Stewart CM, Gauna AE, Dupre LC, Kuklani R, Chan AL, Pauley BA, Reeves WH, Chan EK, Cha S: Altered miR-146a expression in Sjogren’s syndrome and its functional role in innate immunity. Eur J Immunol. 2011, 41: 2029-2039. 10.1002/eji.201040757.CrossRefPubMedPubMedCentral
20.
Sonkoly E, Stahle M, Pivarcsi A: MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol. 2008, 33: 312-315. 10.1111/j.1365-2230.2008.02804.x.CrossRefPubMed
21.
Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A, Stahle M, Pivarcsi A: MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?. PLoS One. 2007, 2: e610. 10.1371/journal.pone.0000610.CrossRefPubMedPubMedCentral
22.
Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, Asahara H: Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008, 58: 1284-1292. 10.1002/art.23429.CrossRefPubMedPubMedCentral
23.
Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008, 10: R101. 10.1186/ar2493.CrossRefPubMedPubMedCentral
24.
Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58: 1001-1009. 10.1002/art.23386.CrossRefPubMed
25.
Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EKL: Elevated STAT1 correlates with increased CCL2 and CXCL10 levels in peripheral blood of patients with systemic lupus erythematosus. Arthritis Res Ther. 2014, 16: R20. 10.1186/ar4448.CrossRefPubMedPubMedCentral
26.
Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis V, Banchereau J, Coffman RL, Pascual V, Barrat FJ: TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature. 2010, 465: 937-941. 10.1038/nature09102.CrossRefPubMedPubMedCentral
27.
Bhattacharyya S, Zhao Y, Kay TW, Muglia LJ: Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate Toll-like receptor-induced STAT1 activation. Proc Natl Acad Sci USA. 2011, 108: 9554-9559. 10.1073/pnas.1017296108.CrossRefPubMedPubMedCentral
28.
Aittomaki S, Pesu M, Groner B, Janne OA, Palvimo JJ, Silvennoinen O: Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. J Immunol. 2000, 164: 5689-5697.CrossRefPubMed
29.
Dall’era M, Chakravarty EF: Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011, 13: 308-316. 10.1007/s11926-011-0186-6.CrossRefPubMedPubMedCentral
30.
31.
Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol. 2003, 21: 335-376. 10.1146/annurev.immunol.21.120601.141126.CrossRefPubMed
32.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982, 25: 1271-1277. 10.1002/art.1780251101.CrossRefPubMed
33.
Nahid MA, Yao B, Dominguez-Gutierrez PR, Kesavalu L, Satoh M, Chan EKL: Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212. J Immunol. 2013, 190: 1250-1263. 10.4049/jimmunol.1103060.CrossRefPubMedPubMedCentral
34.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
35.
Herbst R, Liu Z, Jallal B, Yao Y: Biomarkers for systemic lupus erythematosus. Int J Rheum Dis. 2012, 15: 433-444. 10.1111/j.1756-185X.2012.01764.x.CrossRefPubMed
36.
Hanley JA, Negassa A, Edwardes MD, Forrester JE: Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003, 157: 364-375. 10.1093/aje/kwf215.CrossRefPubMed
37.
Crow MK, Kirou KA, Wohlgemuth J: Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003, 36: 481-490. 10.1080/08916930310001625952.CrossRefPubMed
38.
Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK: Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3958-3967. 10.1002/art.20798.CrossRefPubMed
39.
Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA: Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis. 2008, 67: 1069-1075. 10.1136/ard.2007.074765.CrossRefPubMed
40.
Qing X, Putterman C: Gene expression profiling in the study of the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2004, 3: 505-509. 10.1016/j.autrev.2004.07.001.CrossRefPubMed
41.
Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005, 353: 1711-1723. 10.1056/NEJMra050541.CrossRefPubMed
42.
Hu X, Li WP, Meng C, Ivashkiv LB: Inhibition of IFN-gamma signaling by glucocorticoids. J Immunol. 2003, 170: 4833-4839.CrossRefPubMed
43.
Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME: Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. J Immunol. 2004, 173: 7565-7574.CrossRefPubMed
44.
Kok SH, Hong CY, Kuo MY, Wang CC, Hou KL, Lin YT, Galson DL, Lin SK: Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Arthritis Rheum. 2009, 60: 1451-1462. 10.1002/art.24452.CrossRefPubMed
45.
Valente AJ, Xie JF, Abramova MA, Wenzel UO, Abboud HE, Graves DT: A complex element regulates IFN-gamma-stimulated monocyte chemoattractant protein-1 gene transcription. J Immunol. 1998, 161: 3719-3728.PubMed
46.
Ansari AW, Schmidt RE, Heiken H: Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: in vivo and in vitro findings. Clin Immunol. 2007, 125: 1-4. 10.1016/j.clim.2007.07.003.CrossRefPubMed
47.
Matsuo H, Tamura M, Kabashima N, Serino R, Tokunaga M, Shibata T, Matsumoto M, Aijima M, Oikawa S, Anai H, Nakashima Y: Prednisolone inhibits hyperosmolarity-induced expression of MCP-1 via NF-kappaB in peritoneal mesothelial cells. Kidney Int. 2006, 69: 736-746. 10.1038/sj.ki.5000131.CrossRefPubMed
48.
de Kruif MD, Lemaire LC, Giebelen IA, Groot AP, Pater JM, van den Pangaart PS, Elliott PJ, van der Poll T: Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia. Shock. 2008, 29: 458-461.PubMed
49.
Khodarev NN, Roizman B, Weichselbaum RR: Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Clin Cancer Res. 2012, 18: 3015-3021. 10.1158/1078-0432.CCR-11-3225.CrossRefPubMed
50.
Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum RR: STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA. 2004, 101: 1714-1719. 10.1073/pnas.0308102100.CrossRefPubMedPubMedCentral
51.
Khodarev NN, Minn AJ, Efimova EV, Darga TE, Labay E, Beckett M, Mauceri HJ, Roizman B, Weichselbaum RR: Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res. 2007, 67: 9214-9220. 10.1158/0008-5472.CAN-07-1019.CrossRefPubMed
52.
Kita K, Sugaya S, Zhai L, Wu YP, Wano C, Chigira S, Nomura J, Takahashi S, Ichinose M, Suzuki N: Involvement of LEU13 in interferon-induced refractoriness of human RSa cells to cell killing by X rays. Radiat Res. 2003, 160: 302-308. 10.1667/RR3039.CrossRefPubMed
53.
Rickardson L, Fryknas M, Dhar S, Lovborg H, Gullbo J, Rydaker M, Nygren P, Gustafsson MG, Larsson R, Isaksson A: Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer. 2005, 93: 483-492. 10.1038/sj.bjc.6602699.CrossRefPubMedPubMedCentral
54.
Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O’Dwyer PJ, Johnson SW: Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer. 2005, 92: 1149-1158. 10.1038/sj.bjc.6602447.CrossRefPubMedPubMedCentral
55.
de Prati AC, Ciampa AR, Cavalieri E, Zaffini R, Darra E, Menegazzi M, Suzuki H, Mariotto S: STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem. 2005, 12: 1819-1828. 10.2174/0929867054546645.CrossRefPubMed
Metadata
Title
Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset
Authors
Paul R Dominguez-Gutierrez
Angela Ceribelli
Minoru Satoh
Eric S Sobel
Westley H Reeves
Edward KL Chan
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4451

Other articles of this Issue 1/2014

Arthritis Research & Therapy 1/2014 Go to the issue

Research article

Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren’s syndrome

Research article

Endothelial protein C receptor-associated invasiveness of rheumatoid synovial fibroblasts is likely driven by group V secretory phospholipase A2

Research article

Adiposity and hand osteoarthritis: the Netherlands Epidemiology of Obesity study

Review

Interaction of the endocrine system with inflammation: a function of energy and volume regulation

Research article

The association between ANKH promoter polymorphism and chondrocalcinosis is independent of age and osteoarthritis: results of a case–control study

Research article

Disrupting the Indian hedgehog signaling pathway in vivo attenuates surgically induced osteoarthritis progression in Col2a1-CreER T2 ; Ihhfl/fl mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits